keyword
MENU ▼
Read by QxMD icon Read
search

Skeletal metastases

keyword
https://www.readbyqxmd.com/read/29451848/mr-imaging-of-atraumatic-muscle-disorders
#1
Edward Smitaman, Dyan V Flores, Catalina Mejía Gómez, Mini N Pathria
Atraumatic disorders of skeletal muscles include congenital variants; inherited myopathies; acquired inflammatory, infectious, or ischemic disorders; neoplastic diseases; and conditions leading to muscle atrophy. These have overlapping appearances at magnetic resonance (MR) imaging and are challenging for the radiologist to differentiate. The authors organize muscle disorders into four MR imaging patterns: (a) abnormal anatomy with normal signal intensity, (b) edema/inflammation, (c) mass, and (d) atrophy, highlighting each of their key clinical and imaging findings...
February 16, 2018: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/29435853/do-patients-whose-tumor-achieved-a-pathological-response-relapse-at-specific-sites-a-substudy-of-the-eortc-10994-big-1-00-trial
#2
Kim C Aalders, Nathan Touati, Konstantinos Tryfonidis, Mylène Annonay, Saskia Litiere, Jonas Bergh, Alexandre Bodmer, David A Cameron, Hervé R Bonnefoi
PURPOSE: To determine the sites of first distant relapse in patients with or without pCR following neoadjuvant chemotherapy in breast cancer patients enrolled in the EORTC 10994/BIG-1-00 trial. METHODS: We included patients enrolled in the EORTC 10994/BIG-1-00 trial who received at least one chemotherapy cycle before surgery and who had been diagnosed with a distant relapse. pCR was defined as no evidence of residual invasive cancer in the primary tumor and axillary lymph nodes with or without residual ductal carcinoma in situ...
February 12, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29429912/denosumab-versus-zoledronic-acid-in-bone-disease-treatment-of-newly-diagnosed-multiple-myeloma-an-international-double-blind-double-dummy-randomised-controlled-phase-3-study
#3
Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher, Kazuyuki Shimizu, Ramón García-Sanz, Brian Durie, Wojciech Legieć, Marta Krejčí, Kamel Laribi, Li Zhu, Paul Cheng, Douglas Warner, G David Roodman
BACKGROUND: Multiple myeloma is characterised by monoclonal paraprotein production and osteolytic lesions, commonly leading to skeletal-related events (spinal cord compression, pathological fracture, or surgery or radiotherapy to affected bone). Denosumab, a monoclonal antibody targeting RANKL, reduces skeletal-related events associated with bone lesions or metastases in patients with advanced solid tumours. This study aimed to assess the efficacy and safety of denosumab compared with zoledronic acid for the prevention of skeletal-related events in patients with newly diagnosed multiple myeloma...
February 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29429892/osteosarcoma-subtypes-magnetic-resonance-and-quantitative-diffusion-weighted-imaging-criteria
#4
Rania Zeitoun, Ahmed M Shokry, Sahar Ahmed Khaleel, Shaimaa M Mogahed
INTRODUCTION: Osteosarcoma (OS) is a primary bone malignancy, characterized by spindle cells producing osteoid. The objective of this study is to describe the magnetic resonance imaging (MRI) features of different OS subtypes, record their attenuation diffusion coefficient (ADC) values and to point to the relation of their pathologic base and their corresponding ADC value. PATIENTS AND METHODS: We performed a retrospective observational lesion-based analysis for 31 pathologically proven osteosarcoma subtypes: osteoblastic (n = 9), fibroblastic (n = 8), chondroblastic (n = 6), para-osteal (n = 3), periosteal (n = 1), telangiectatic (n = 2), small cell (n = 1) and extra-skeletal (n = 1)...
February 8, 2018: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/29426963/prostate-specific-membrane-antigen-psma-expression-in-breast-cancer-and-its-metastases
#5
Mariz Kasoha, Clara Unger, Erich-Franz Solomayer, Rainer M Bohle, Claudia Zaharia, Fadi Khreich, Stefan Wagenpfeil, Ingolf Juhasz-Böss
The present study was undertaken to investigate the expression of prostate-specific membrane antigen (PSMA) in normal breast tissues, in cancerous breast tissues and in distant metastases from patients with breast cancer. Immunohistochemical analysis was performed to determine PSMA expression and angiogenic activity using anti-PSMA mAb and anti-CD31 mAb respectively. Immunofluorescence staining was applied to confirm the exact co-localization of PSMA and CD31. We observed different patterns of PSMA expression between normal and cancerous tissues...
February 10, 2018: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29420197/muscle-metastases-rare-problem-with-unusual-solution
#6
Becky Hirst, Jack Powell
Skeletal muscle is an unusual site for metastasis from malignancy. We report a patient who presented with calf metastases from a squamous cell carcinoma of lung. Attempts were made to control his pain conservatively for almost 2 years before he was referred for a below-knee amputation. He did well following this and was able to stop the majority of his analgesic drugs.
February 1, 2018: BMJ Supportive & Palliative Care
https://www.readbyqxmd.com/read/29416877/idk1-is-a-rat-monoclonal-antibody-against-hypoglycosylated-bone-sialoprotein-with-application-as-biomarker-and-therapeutic-agent-in-breast-cancer-skeletal-metastasis
#7
Michael Zepp, Marineta Kovacheva, Munkhtsetseg Altankhuyag, Gabriela Westphal, Irina Berger, Katharina S Gather, Heidegard Hilbig, Jochen Neuhaus, Gertrud M Hänsch, Franz P Armbruster, Martin R Berger
Changes in glycosylation are salient features of cancer cells. Here, we report on the diagnostic and therapeutic properties of IDK1, an antibody against tumour associated, hypoglycosylated bone sialoprotein (hypo-BSP). The affinity of the rat monoclonal antibody IDK1 for hypo-BSP, as determined by microscale thermophoresis, was three orders of magnitude higher than for mature BSP, whereas the mouse monoclonal antibody used had similar affinity for both BSP forms. IDK1 showed no activity against the proliferation or migration of normal or cancer cells growing in vitro...
January 2018: Journal of Pathology. Clinical Research
https://www.readbyqxmd.com/read/29401146/177lu-prostate-specific-membrane-antigen-super-scan-and-good-response-even-after-1-cycle-of-radioligand-therapy
#8
Kamran Aryana, Soroush Zarehparvar Moghadam, Roham Salek, Ghasemali Divband
A 76-year-old man with castration-resistant prostate cancer and widespread skeletal metastases underwent 2 cycles of Lu-prostate-specific membrane antigen (PSMA) 617 therapy in our department. Whole-body Lu-PSMA scan after the first cycle showed diffuse skeletal PSMA-avid lesions, whereas no PSMA uptake was evident in the kidneys with minimal PSMA uptake by salivary glands (super scan). After 6 weeks, he received the second dose of Lu-PSMA and whole-body scan after the treatment showed remarkable resolution of skeletal metastases and normal PSMA uptake by the kidneys and salivary glands...
February 3, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29396636/imaging-%C3%AE-v%C3%AE-3-integrin-expression-in-skeletal-metastases-with-99mtc-maraciclatide-single-photon-emission-computed-tomography-detection-and-therapy-response-assessment
#9
Gary J R Cook, Gurdip K Azad, Benjamin P Taylor, Eugene Lee, Matthew S Morrison, Simon Hughes, Stephen Morris, Sarah Rudman, Simon Chowdhury, Vicky Goh
PURPOSE: Osteoclast activity is an important factor in the pathogenesis of skeletal metastases and is a potential therapeutic target. This study aimed to determine if selective uptake of 99mTc-maraciclatide, a radiopharmaceutical targeting αvβ3 integrin, occurs in prostate cancer (PCa) bone metastases and to observe the changes following systemic therapy. METHODS: The study group comprised 17 men with bone-predominant metastatic PCa who underwent whole-body planar and single-photon emission computed tomography/computed tomography (SPECT/CT) imaging with 99mTc-maraciclatide before (n = 17) and 12 weeks after (n = 11) starting treatment with abiraterone...
February 2, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29390509/skeletal-related-events-and-overall-survival-of-patients-with-bone-metastasis-from-nonsmall-cell-lung-cancer-a-retrospective-analysis
#10
Pengyu Kong, Jinglong Yan, Donghui Liu, Ye Ji, Yufu Wang, Jinpeng Zhuang, Jincai Wang, Xiaowei Hu, Xiaolong Yue
Because of improving treatments and survival, 40% to 58% of patients with bone metastases from nonsmall cell lung cancer (NSCLC) will suffer from at least one skeletal-related event (SRE), affecting their quality of life, but the natural history of SRE is poorly understood. The study aimed to examine the factors involved in SRE-free survival (SRS) and overall survival (OS) of patients with NSCLC and bone metastases.This was a retrospective study of 211 patients with bone metastasis from NSCLC and treated at the Tumor Hospital Affiliated to Harbin Medical University between January 2007 and January 2012...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29389236/response-to-cost-effectiveness-analysis-of-zoledronic-acid-once-per-month-zoledronic-acid-once-every-3-months-and-denosumab-once-per-month-in-women-with-breast-cancer-and-skeletal-metastases
#11
Lisa Kennedy, Sumita Bhatta, Guy Hechmati, Jacqueline Buchanan
No abstract text is available yet for this article.
February 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29388038/bladder-cancer-presenting-with-acrometastases-a-different-cause-of-foot-pain
#12
João Matos, Ilaria Mussetto, Raffaella Podestà, Daria Schettini, Nicoletta Gandolfo
Acrometastasis means tumor seeding distally to the elbow or the knee and is an uncommon event. Foot acrometastases occur in 0.58% of patients with skeletal metastases overall, and only about 10% of these are caused by bladder cancer. We present a case of bladder cancer manifesting with insidious foot pain, caused by multiple lytic lesions located solely at the left foot. It was suspected after whole-body CT and later confirmed by biopsy result. We enumerate the differential diagnosis of distal extremity lytic lesions for educational purposes and review the literature listing similar published cases...
February 1, 2018: Skeletal Radiology
https://www.readbyqxmd.com/read/29378475/commentary-on-some-recent-theses-relevant-to-combating-aging-february-2018
#13
Benjamin Zealley, Aubrey D N J de Grey
Theses reviewed in this issue include "Characterizing Senescence in Astrocytes and its Effect on Neurons", "Contribution of Adult Skeletal Muscle Stem Cells to the Regeneration and Lifelong Maintenance of Neuromuscular Junctions", "Investigation into Feasibility of Color and Texture Features for Automated Detection of Lymph Node Metastases in Histopathological Images", "Stem Cell Engineered Invariant Natural Killer T Cells for Cancer Immunotherapy", "Supramolecular Peptide Nanofibers for Active Immunotherapy", and "Visualisation and Monitoring of Tumour-Mediated Immune Modulation in Primary Cancer and Premetastatic Niche Establishment Using S100A8/A9-Specific Imaging"...
January 29, 2018: Rejuvenation Research
https://www.readbyqxmd.com/read/29370211/osteoclast-inhibitors-to-prevent-bone-metastases-in-men-with-high-risk-non-metastatic-prostate-cancer-a-systematic-review-and-meta-analysis
#14
Aimee R Hayes, Daniel Brungs, Nick Pavlakis
BACKGROUND: In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events associated with bone metastases. However, it is uncertain whether they play a disease-modifying role earlier in the course of the disease. METHODS: Medline, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews and ASCO conference proceedings were searched for randomized controlled trials that compared osteoclast inhibitors with placebo and/or standard of care (SOC) in patients with high-risk, non-metastatic prostate cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29362859/68ga-psma-pet-ct-in-the-evaluation-of-bone-metastases-in-prostate-cancer
#15
Christos Sachpekidis, P Bäumer, K Kopka, B A Hadaschik, M Hohenfellner, A Kopp-Schneider, U Haberkorn, A Dimitrakopoulou-Strauss
PURPOSE: The aims of this retrospective analysis were to compare 68Ga-PSMA PET findings and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative 68Ga-PSMA PET data in patients with prostate cancer (PC) bone metastases. METHODS: In total, 152 PET/CT scans from 140 patients were evaluated. Of these patients, 30 had previously untreated primary PC, and 110 had biochemical relapse after treatment of primary PC. All patients underwent dynamic PET/CT scanning of the pelvis and lower abdomen as well as whole-body PET/CT with 68Ga-PSMA-11...
January 23, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29356736/anaplastic-thyroid-cancer-with-extensive-skeletal-muscle-metastases-on-18f-fdg-pet-ct
#16
Ilana R Yurkiewicz, Kristen N Ganjoo, Andrei Iagaru
A 61-year-old woman with newly diagnosed anaplastic thyroid cancer and known metastases to the brain, lungs, and adrenal glands complained of groin muscle pain. F-FDG PET/CT was performed to assess for extent of disease and showed extensive hypermetabolic lesions throughout the skeletal musculature concerning for metastatic disease. As this would be a very rare presentation for anaplastic thyroid carcinoma, a biopsy of the left gluteal muscle was conducted. Pathology demonstrated anaplastic thyroid carcinoma, metastatic to skeletal muscle...
January 19, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29337860/reporting-and-handling-of-indeterminate-bone-scan-results-in-the-staging-of-prostate-cancer-a-systematic-review
#17
Lars J Petersen, Jesper Strandberg, Louise Stenholt, Martin B Johansen, Helle D Zacho
Bone scintigraphy is key in imaging skeletal metastases in newly diagnosed prostate cancer. Unfortunately, a notable proportion of scans are not readily classified as positive or negative but deemed indeterminate. The extent of reporting of indeterminate bone scans and how such scans are handled in clinical trials are not known. A systematic review was conducted using electronic databases up to October 2016. The main outcome of interest was the reporting of indeterminate bone scans, analyses of how such scans were managed, and exploratory analyses of the association of study characteristics and the reporting of indeterminate bone scan results...
January 16, 2018: Diagnostics
https://www.readbyqxmd.com/read/29305799/prevention-of-serious-skeletal-related-events-by-interventional-radiology-techniques-in-patients-with-malignant-paraganglioma-and-pheochromocytoma
#18
Guillaume Gravel, Sophie Leboulleux, Lambros Tselikas, Flora Fassio, Mohamed Berraf, Amandine Berdelou, Bakar Ba, Segolene Hescot, Julien Hadoux, Martin Schlumberger, Abir Al Ghuzlan, France Nguyen, Mathieu Faron, Thierry de Baere, Eric Baudin, Frederic Deschamps
PURPOSE: Bone metastases (BM) and skeletal-related events (SRE) are frequent in patients with malignant pheochromocytoma and paraganglioma (PPM) and the best modality of prevention unknown. The role of interventional radiology (IR) techniques for the prevention of SRE in the multidisciplinary management of malignant PPM has not been evaluated in that setting. METHODS: Single referral center retrospective review of all patients with malignant PPM with BM from 2000 to 2016...
January 5, 2018: Endocrine
https://www.readbyqxmd.com/read/29300334/understanding-the-progression-of-bone-metastases-to-identify-novel-therapeutic-targets
#19
REVIEW
Annie Schmid-Alliana, Heidy Schmid-Antomarchi, Rasha Al-Sahlanee, Patricia Lagadec, Jean-Claude Scimeca, Elise Verron
Bone is one of the most preferential target site for cancer metastases, particularly for prostate, breast, kidney, lung and thyroid primary tumours. Indeed, numerous chemical signals and growth factors produced by the bone microenvironment constitute factors promoting cancer cell invasion and aggression. After reviewing the different theories proposed to provide mechanism for metastatic progression, we report on the gene expression profile of bone-seeking cancer cells. We also discuss the cross-talk between the bone microenvironment and invading cells, which impacts on the tumour actions on surrounding bone tissue...
January 4, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29300279/disease-modifying-actions-of-il-6-blockade-in-a-rat-model-of-bone-cancer-pain
#20
Bethany Remeniuk, Tamara King, Devki Suktankhar, Amy Nippert, Nancy Li, Fuying Li, Kejun Cheng, Kenner C Rice, Frank Porreca
Metastasis of cancer to the skeleton represents a debilitating turning point in the lives of patients. Skeletal metastasis leads to moderate to severe ongoing pain along with bone remodeling that can result in fracture, events that dramatically diminish quality of life. IL-6 levels are elevated in metastatic breast cancer patients and are associated with a lower survival rate. We therefore determined the consequences of inhibition of IL-6 signaling using a novel small molecule antagonist, TB-2-081, on bone integrity, tumor progression, and pain in a rodent model of breast cancer...
December 26, 2017: Pain
keyword
keyword
109657
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"